Literature DB >> 29551256

Elevated serum uric acid increases risks for developing high LDL cholesterol and hypertriglyceridemia: A five-year cohort study in Japan.

Masanari Kuwabara1, Claudio Borghi2, Arrigo F G Cicero2, Ichiro Hisatome3, Koichiro Niwa4, Minoru Ohno5, Richard J Johnson6, Miguel A Lanaspa6.   

Abstract

BACKGROUND: High serum uric acid (SUA) is associated with the dyslipidemia, but whether hyperuricemia predicts an increase in serum low-density lipoprotein (LDL) cholesterol is unknown. This study is to evaluate whether an elevated SUA predicts the development of high LDL cholesterol as well as hypertriglyceridemia.
METHODS: This is a retrospective 5-year cohort study of 6476 healthy Japanese adults (age, 45.7 ± 10.1 years; 2.243 men) who underwent health examinations at 2004 and were reevaluated in 2009 at St. Luke's International Hospital, Tokyo, Japan. Subjects were included if at their baseline examination they did not have hypertension, diabetes mellitus, dyslipidemia, chronic kidney disease, or if they were on medication for hyperuricemia and/or gout. The analysis was adjusted for age, body mass index (BMI), smoking and drinking habits, baseline estimated glomerular filtration rate (eGFR), baseline SUA and SUA change over the 5 years.
RESULTS: High baseline SUA was an independent risk for developing high LDL cholesterol both in men (OR: 1.159 per 1 mg/dL increase, 95% CI:1.009-1.331) and women (OR: 1.215, 95% CI:1.061-1.390). Other risk factors included a higher baseline LDL cholesterol, higher BMI, and higher baseline eGFR (the latter two in women only). Increased SUA over 5 years were also independent risks for developing high LDL cholesterol and hypertriglyceridemia, but not for low high-density lipoprotein (HDL) cholesterol.
CONCLUSIONS: This is the first study to report that an elevated SUA increases the risk for developing high LDL cholesterol, as well as hypertriglyceridemia. This may shed light into the role of SUA in cardiovascular disease.
Copyright © 2018 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Epidemiology; Hypertriglyceridemia; Low-density lipoprotein cholesterol; Risk factor; Uric acid

Mesh:

Substances:

Year:  2018        PMID: 29551256     DOI: 10.1016/j.ijcard.2018.03.045

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  37 in total

1.  Expert consensus for the diagnosis and treatment of patient with hyperuricemia and high cardiovascular risk: 2021 update.

Authors:  Claudio Borghi; Justyna Domienik-Karłowicz; Andrzej Tykarski; Krystyna Widecka; Krzysztof J Filipiak; Miłosz J Jaguszewski; Krzysztof Narkiewicz; Giuseppe Mancia
Journal:  Cardiol J       Date:  2021-01-13       Impact factor: 2.737

2.  Metabolomic characterization of hypertension and dyslipidemia.

Authors:  Chaofu Ke; Xiaohong Zhu; Yuxia Zhang; Yueping Shen
Journal:  Metabolomics       Date:  2018-08-31       Impact factor: 4.290

3.  Uric acid drives intestinal barrier dysfunction through TSPO-mediated NLRP3 inflammasome activation.

Authors:  Qiulan Lv; Daxing Xu; Jinfeng Ma; Yan Wang; Xiaomin Yang; Peng Zhao; Liang Ma; Zhiyuan Li; Wan Yang; Xiu Liu; Guanpin Yang; Shichao Xing
Journal:  Inflamm Res       Date:  2020-10-19       Impact factor: 4.575

4.  Protective Effects of α-Lipoic Acid on Vascular Oxidative Stress in Rats with Hyperuricemia.

Authors:  Wei Xiang; Li Wang; Shi Cheng; Yong Zhou; Ling Ma
Journal:  Curr Med Sci       Date:  2019-12-16

Review 5.  Therapeutic implications of shared mechanisms in non-alcoholic fatty liver disease and chronic kidney disease.

Authors:  Mehmet Kanbay; Mustafa C Bulbul; Sidar Copur; Baris Afsar; Alan A Sag; Dimitrie Siriopol; Masanari Kuwabara; Silvia Badarau; Adrian Covic; Alberto Ortiz
Journal:  J Nephrol       Date:  2020-05-21       Impact factor: 3.902

6.  Uric acid activates aldose reductase and the polyol pathway for endogenous fructose and fat production causing development of fatty liver in rats.

Authors:  Laura G Sanchez-Lozada; Ana Andres-Hernando; Fernando E Garcia-Arroyo; Christina Cicerchi; Nanxing Li; Masanari Kuwabara; Carlos A Roncal-Jimenez; Richard J Johnson; Miguel A Lanaspa
Journal:  J Biol Chem       Date:  2019-01-16       Impact factor: 5.157

Review 7.  Roles of hyperuricemia in metabolic syndrome and cardiac-kidney-vascular system diseases.

Authors:  Hongsha Wang; Haifeng Zhang; Lin Sun; Weiying Guo
Journal:  Am J Transl Res       Date:  2018-09-15       Impact factor: 4.060

8.  Serum uric acid and risk of incident hypercholesterolaemia and hypertriglyceridaemia in middle-aged and older Chinese: a 4-year prospective cohort study.

Authors:  Yanzhi Li; Lu Tian; Han Zheng; Chongqi Jia
Journal:  Ann Med       Date:  2020-07-22       Impact factor: 4.709

9.  Hyperuricemia and hypertriglyceridemia indicate tubular atrophy/interstitial fibrosis in patients with IgA nephropathy and membranous nephropathy.

Authors:  Bingman Liu; Liangyu Zhao; Qingqing Yang; Dongqing Zha; Xiaoyun Si
Journal:  Int Urol Nephrol       Date:  2021-04-24       Impact factor: 2.370

10.  Association between Lipid Profiles and Serum Urate: A Cross-Sectional Study in Southwestern China.

Authors:  Jiying Qi; Xiaojuan Dai; Binbin Zhou; Yang Su; Zhen Xie; Dongmei Liu
Journal:  Int J Endocrinol       Date:  2021-07-08       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.